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ABSTRACT 
 
HLA-DR1 transgenic (DR1 Tg) mice provide a model for evaluating 
the breadth and specificity of CD4 T cell responses that may develop in 
humans following influenza infection or vaccination. Recent studies 
identified a tremendously broad HLA-DR1-restricted CD4 T cell responses 
in DR1 Tg mice infected intranasally with influenza A/New 
Caledonia/20/99 (NC). In this study, our goals were to characterize B cell 
responses after NC infection in DR1 Tg mice and establish the correlation 
between B cell responses and CD4 T cell responses in this system. 
Influenza-specific B cell responses following virus administration were 
analyzed in DR1 Tg mice and in the genetically matched H-2b strain 
C57BL/10J (B10).  
 
Following intranasal (i.n.) NC infection, B cell responses in B10 mice 
featured strong IgG2b and IgG2c production and were typical of previously 
described B cell responses to a variety of mouse-adapted influenza strains. 
In contrast, B cell responses in DR1 Tg mice followed delayed kinetics 
and were strongly skewed to IgG1 production, suggesting the Th2 
polarization of CD4 T cell responses. The different antibody isotype profile 
in DR1 Tg mice compared to B10 mice was evident in antibody secreting 
cells (ASCs) frequencies and in circulating Abs levels. Surprisingly, 
although DR1 Tg mice had lower influenza-specific Abs levels, they 
exhibited higher neutralizing Abs titers early in the response.  
 
B cell responses following intranasal infection of influenza A/Puerto 
Rico/8/1934 (PR8) or intramuscular vaccination of inactivated NC in DR1 
Tg mice were different from the observed IgG1 bias after i.n. NC infection. 
After i.n. PR8 infection, B cell responses were characterized by 
predominant IgM/IgG3 production, which was similar in DR1 Tg mice and 
 iv 
B10 mice. Additionally, following intramuscular administration of 
inactivated NC, B cell responses were skewed towards IgG2c production 
in both DR1 Tg mice and B10 mice, suggesting the Th1 polarization of 
CD4 T cell responses. A mechanistic understanding of IgG1/Th2 biased B 
cell responses and better neutralizing Abs production in DR1 Tg mice 
following i.n. NC infection may have implications for the optimal control of 
influenza infection. 
 v 
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CHAPTER 1 
INTRODUCTION 
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I. Overview of influenza viruses 
 
The influenza virus is one of the most important human respiratory 
pathogens and attacks the host respiratory tract mucosa, causing 
seasonal outbreaks, endemic infections and periodic pandemics [1]. 
Influenza viruses are enveloped viruses belonging to the family 
Orthomyxoviridae and contain a negative, segmented, single-stranded 
RNA genome [2]. Based on antigenic differences of core proteins, 
nucleoprotein (NP) and matrix protein (M), influenza viruses are divided 
into types A, B and C [3]. Based on antigenic differences of two surface 
glycoproteins, hemagglutinin (HA) and neuraminidase (NA), type A viruses 
are further subdivided into subtypes [3]. Currently, 16 HA (H1-H16) and 9 
NA (N1-N9) subtypes have been identified in influenza A viruses [4]. 
 
Influenza A viruses have been isolated from various animals, 
including birds, pigs, horses, humans and sea mammals, whereas type B 
and C influenza viruses are predominantly found in humans [5]. Influenza 
A and B viruses cause annual epidemics or local outbreaks of influenza in 
humans [1]. All different subtypes of influenza A can be found in avian 
hosts, and therefore aquatic birds are thought to be the natural reservoir of 
influenza A viruses [6]. However, since the last century, only H1N1, H2N2, 
and H3N2 subtypes have been associated with widespread epidemics in 
humans [2]. Although a number of avian influenza viruses  (H5N1, H9N2, 
and H7N7) have crossed the species barrier and directly infected humans, 
they still have not developed the capacity for efficient human-to-human 
transmission [3].  
 
Genetics of the influenza A virus 
 
The genome of influenza A viruses (Fig. 1) contains eight single-
stranded, negative-sense RNA segments and codes for at least 10 
proteins in vivo by using different reading frames and alternative RNA 
splicing [3]. The virus particle has a lipid envelope that is derived from the 
host cell during budding through the cell membrane [5]. Three proteins are 
embedded in the lipid bilayer: the rod-shaped HA, the mushroom-shaped 
NA, and the matrix protein 2 (M2) [3]. The matrix protein 1 (M1) is the 
most abundant protein in the virus particle and locates right below the lipid 
bilayer [7, 8]. Genomic RNA segments are encapsulated with the 
nucleoprotein (NP) and are associated with three RNA polymerase 
proteins (PB1, PB2, PA) to form ribonucleoprotein (RNP) complex [3, 9]. 
The virus also encodes nonstructural proteins NS1 and NS2. NS1 
counteracts the type I interferon antiviral program of host cells by 
sequestering viral RNAs from intracellular receptors; NS2, also referred to 
as the nuclear export protein (NEP), is involved in the process of nuclear 
export of RNPs and viral assembly [10].  
 
 
 
Figure 1. Structure of the influenza A virus [7] 
 
 
 
 3
 4
Two major surface glycoproteins, HA and NA, are the most important 
targets of neutralizing Abs during influenza infection [1, 11]. HA is 
responsible for the binding of viruses to sialic acid-containing receptors 
and the membrane fusion between the virus and the host, resulting in the 
release of viral RNPs into host cells [8]. NA cleaves sialic acid residues of 
cellular receptors and releases new viruses [3]. 
 
Pathogenesis of the influenza A virus 
 
Influenza is an acute and contagious respiratory disease, 
characterized by the sudden onset of systemic and respiratory symptoms 
including fever, headache, cough, sore throat and rhinitis etc. [3]. All 
influenza A subtypes are carried in the gastrointestinal tract of wild birds 
asymptomatically, but may cause diseases in domestic birds and 
mammals [12].  
 
Influenza viruses are constantly undergoing antigenic changes to 
escape the host adaptive immunity in two ways: antigenic shift and 
antigenic drift [3]. Due to the segmented viral genome, influenza viruses 
can easily reassort segments from different strains in a doubly infected 
host [3]. The reassortment will result in the emergence of a new subtype 
with novel antigenic properties, referred to as antigenic shift [3]. Antigenic 
shift can also occur when an avian strain is directly transmitted to humans 
without reassortment [13]. Antigenic shift happens at infrequent and 
unpredictable intervals. Since a large proportion of human populations 
have little or no immunity to the new subtype and antibodies against the 
previously circulating strain do not cross-react with it, the new subtype 
possesses the potential to cause a global pandemic [3, 8]. Viruses 
causing the pandemics of 1957 and 1968 were derived from the 
reassortment of avian and human viruses [14, 15]. 
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Antigenic drift results from the continuous accumulation of minor 
genetic mutations in all gene segments, mostly in surface glycoproteins 
HA and NA [3]. Viral RNA-dependent RNA polymerase complex lacks 
proofreading abilities, resulting in high rates of point mutations (~ 1/104 
base per replication cycle) during genome replication [16]. Variant strains 
of the same subtype contribute to annual epidemics or local outbreaks of 
influenza. 
 
The binding specificity of HA for host cells is thought to be a major 
determinant of whether an influenza strain can infect a host [7]. An 
important difference between avian and human viruses is their binding 
preferences for specific sialic acid linkages on host cells [2]. Most avian 
influenza viruses preferentially bind to α-2,3 sialic acid linkages, whereas 
human strains preferentially bind to α-2,6 sialic acid linkages [17, 18]. 
Upper respiratory tract epithelial cells of birds and human preferentially 
express virus receptors with α-2,3 sialic acid linkages and α-2,6 sialic acid 
linkages, respectively, whereas respiratory epithelial cells of pigs express 
receptors with both α-2,3 and α-2,6 sialic acid linkages [19].   
 
The receptor binding specificity and expression pattern has led to the 
hypothesis that pigs serve as a “mixing vessel” which facilitates antigenic 
shift [15, 19]. When pigs are infected with human and avian viruses 
simultaneously, reassortment may occur to give rise to a new pandemic 
strain with efficient human-to-human transmission capacity [7]. The 
receptor binding specificity and expression pattern also accounts for the 
usual restriction of infection by avian strains to birds and pigs but not 
humans [2]. However, research showed that a human virus A/New 
Caledonia/20/99 was able to replicate effectively in mice lacking α-2,6 
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sialic acid linkages, indicating that this restriction was not totally absolute 
[20]. 
 
HA is synthesized as an HA0 precursor, which needs to be cleaved 
into two subunits HA1 and HA2 by host proteases at a conserved arginine 
residue [7, 9]. HA of highly pathogenic avian influenza (HPAI) has a series 
of basic amino acids at the cleavage site enabling HA to be cleaved by 
ubiquitous proteases, which facilitates systemic infection and spread of 
the virus [21]. Therefore, HA cleavability is considered as another major 
determinant of virus pathogenicity. 
 
Other gene segments can also contribute to the pathogenicity of 
influenza viruses. It is still not clear what resulted in the extreme virulence 
of the extinguished 1918 pandemic strain. Research based on the 
successful reconstruction of this strain showed that HA, NA, and PB1 
genes were responsible for the high replication efficiency of the 
reconstructed strain observed in mouse and human airway cells [22]. PB1 
gene probably played a crucial role in the 1918 virus virulence [22]. PB2 
gene appeared to contribute to the efficient transmission of viruses by 
allowing enhanced replication at a lower temperature in the airway of 
mammals [23].  
 
Epidemiology 
 
Influenza epidemics usually occur between November and March in 
the northern hemisphere and between April and September in the 
southern hemisphere [2]. Influenza is responsible for over 100,000 
hospitalizations and around 20,000 deaths annually in the US [24, 25]. 
During a pandemic, which usually happens every several decades, the 
morbidity and mortality increase dramatically.  
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There were three influenza pandemics in the last century [26]. The 
1918-1919 Spanish influenza was caused by a H1N1 strain and killed 
more that 40 million people [27]. Almost 50% of deaths occurred in an 
unusually young age group, 20-40-year-olds [28]. A new influenza H2N2 
virus was responsible for the 1957 Asian influenza pandemic and was first 
isolated in Japan in May 1957 [2]. A H3N2 strain caused the third 
pandemic and was isolated at Hong Kong in 1968 [2]. This strain 
contained avian HA (H3) and PB1 segments, and shared other segments 
with the previously circulating H2N2 virus [5]. 
 
In late March and early April 2009, an outbreak of H1N1 influenza A 
virus infection was detected in Mexico, followed by many other countries 
including the US [29]. The pandemic (H1N1) 2009 influenza A virus is a 
new reassortant comprising two swine strains, one human strain and one 
avian strain [26]. Recent data from numerous outbreak sites show that the 
pandemic (H1N1) 2009 virus is currently the dominant strain circulating in 
most parts of the world [30]. 
 
II. The immune response to influenza viruses 
 
The respiratory tract mucosa is not only the site of influenza infection 
but also the site of defense against influenza infection in the host [1]. The 
kinetics study of the influenza A virus showed that infected epithelial cells 
started to produce viruses 6 hours after infection [31]. The virus titer in the 
lung usually peaks 2-3 days post-infection, and becomes undetectable 
around 10 days post-infection [32]. However, the host adaptive immune 
response needs about one week to develop [32]. Therefore, in order to 
control virus infection or recover from influenza, both innate and adaptive 
immune responses should be induced [1]. 
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Innate immunity to influenza viruses 
 
The innate immune response triggered by virus infection functions as 
the first line of defense to restrict viral spread. The innate system consists 
of effector cells (such as epithelial cells, NK cells, macrophages, and 
plasmacytoid dendritic cells), cytokines and chemokines (including IFNs, 
TNF-α, IL-1, IL-6, IL-12, MIP-1, IP-10), and complements [1, 33]. The 
recognition of viral RNAs by TLRs induces the production of cytokines and 
chemokines by infected lung epithelial cells and macrophages [34, 35]. 
The cytokines and chemokines then contribute to attracting monocytes 
and T cells from peripheral blood into the site of infection within the first 3 
days after infection [34]. 
 
Type I IFNs, which are produced by infected epithelial cells, 
macrophages, and plasmacytoid dendritic cells, are important components 
of the innate immune response due to their direct antiviral effects [7]. The 
IFN-α/β response starts within 12 hours after infection and lasts for 
several days [36].  Type I IFNs influence CD4 differentiation resulting in 
the development of Th1 effector cells that in turn produce high levels of 
IFN-γ and IL-2 [37]. 
 
Adaptive immunity to influenza viruses 
 
After influenza viruses successfully escape the innate immune 
response and establish intracellular infection, the adaptive immune system 
will play a key role in the host defense by detecting and eliminating 
infected cells [38]. The adaptive immunity is comprised of cell-mediated 
immune system and humoral immune system. 
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The cell-mediated immune system, consisting of CD4 T cells and 
CD8 T cells, is essential for virus clearance during influenza infection [3]. 
CD8 T cells, also called cytotoxic lymphocytes (CTLs), recognize an 
antigenic peptide-MHC class I complex through TCRs and become 
activated [1]. Activated CTLs not only directly lyse infected cells, but also 
secret pro-inflammatory and anti-viral cytokines, such as IFNs [39]. CD4 T 
cells recognize antigenic peptide-MHC class II complex on APCs and then 
differentiate into different subtypes, such as Th1, Th2, Treg, and Th17 [40]. 
Th1 cells secrete IFN-γ and IL-2, and provide help for CD8 T cells 
proliferation and IgG2a/IgG2c production by antibody secreting cells 
(ASCs); Th2 cells secrete IL-4 and IL-5, and help IgA, IgG1 and IgE 
production by ASCs [34]. 
 
The humoral immune system relies on the production of antibodies 
by B cells to protect against influenza. Virus-specific Abs against HA and 
NA are thought to be the most protective [32]. Anti-HA Abs neutralize the 
infectivity of viruses, and anti-NA Abs reduce the release of viruses from 
infected cells [41]. Abs to the conserved protein M2 are cross-protective 
among different subtypes, while Abs to the conserved NP and M1 fail to 
contribute to protection [42, 43]. The secretory IgA (sIgA) produced locally 
at mucosal sites is the major neutralizing antibody to prevent virus 
entrance especially at the upper respiratory tract [3].   
 
Long-lived plasma cells and memory B cells also contribute to the 
protective immune response [44]. They are able to induce rapid recall 
responses and produce high-affinity antibodies to neutralize viruses, which 
are important to control the spread of viruses during the early stage of 
infection [45]. Long-lived plasma cells reside in the bone marrow after 
infection and constitute the main source of circulating antibodies in serum 
as well as antibodies at mucosa sites [46]. Memory B cells usually 
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circulate and disperse to secondary lymphoid organs throughout the body 
[47]. An analysis of memory B cells induced by influenza infection 
identified the lung as a non-lymphoid site where memory B cells as well as 
ASCs preferentially localize [48]. 
 
III. B cell activation, proliferation and differentiation 
 
After their generation and maturation in the bone marrow, naïve B 
cells migrate to the blood and enter secondary lymphoid organs through 
high endothelial venules (HEVs) in the outer T cell zone and interfollicular 
regions [49, 50]. B cells then migrate to B cell follicles where they are 
retained for up to 24 hours to scan for specific antigens [49]. This 
migration is dependent on the expression of CXCR5 by B cells and its 
ligand CXCL13 by follicular stromal cells [51]. Inside follicles B cells are 
highly motile in a “random walk” fashion and search for antigens [52].  
 
So how do antigens get into lymph nodes from outside and where do 
B cells encounter antigens?  Antigens of low molecular weight can freely 
diffuse into B cell follicles via pores on the floor of subcapsular sinus (SCS) 
[53]. Antigens can also travel through conduits into B cell follicles [54]. 
Dendritic cells (DCs) use Fc receptor FcγRIIB to non-degradatively uptake 
antigens and then migrate to the T cell zone [55]. Therefore newly arriving 
B cells via HEVs have the chance to encounter antigen-bearing DCs 
during their migration to B cell follicles [50]. 
 
Recently, the use of two-photon microscopy identified the SCS 
macrophage as another important antigen encounter site within the first 
few hours of the immune response [56-58]. When antigens entered LNs 
via lymph flow, SCS macrophages captured immune complexes (ICs), 
viruses or virus-like particles, and then presented intact antigens to 
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follicular B cells [59]. Noncognate B cells were observed to capture ICs 
from SCS macrophages by complement receptor 1 and 2 (CR1/2) and 
deliver these ICs to follicular dendritic cells (FDCs) within follicles [58]. 
FDCs as specialized Ag-trapping cells within follicles can retain ICs on 
their surface and present intact antigens to B cells [59].  
 
After encountering antigens in B cell follicles, B cells recognize and 
bind to antigens by the B cell receptor (BCR) [60]. The BCR consists of 
membrane immunoglobulin (mIg) associated with Igα-Igβ heterodimers 
[61]. Antigens are internalized through binding to BCRs, processed within 
specific endosomal compartments, and finally presented in complexes 
with MHC class II molecules [62]. Antigen-engaged B cells then migrate to 
the B-T boundary where activated T cells also relocate [50]. B cells can be 
retained there to allow for encountering CD4 helper T cells and forming 
stable cognate T-B interactions to get essential help signals for further 
differentiation. Then activated B cells can undergo one of two 
differentiation pathways: the extrafollicular pathway or the germinal center 
pathway [63, 64]. 
 
In the extrafollicular pathway, activated B cells migrate to sites 
without T cells and differentiate into plasmablasts [65, 66]. After ~3 days 
these plasmablasts further differentiate into short-lived plasma cells to 
secrete antibodies with low affinities [67]. In the germinal center reaction, 
activated B cells migrate to the center of B cell follicles and proliferate 
within the FDCs network, resulting in the formation of the germinal center 
(GC) [64]. The GC is the main site of supporting the antibody affinity 
maturation and the generation of memory B cells. The dark zone and the 
light zone are termed in the GC on the basis of their histological 
appearances [68].  
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According to a classic model of antibody affinity maturation, B cells in 
the dark zone, called “centroblasts”, undergo extensive proliferation and 
somatic hypermutation [68]. Centroblasts then migrate to the light zone 
and differentiate into smaller “centrocytes” [68]. Centrocytes undergo the 
selection for high affinity BCRs with the help of FDCs and Follicular helper 
T (Tfh) cells [68]. FDCs are capable of capturing large amount of intact 
antigens in the form of ICs [69]. The follicular helper T cell is a subset of 
activated CD4 T cells [70]. By competing for binding to antigens displayed 
on the surface of FDCs, B cells with high affinity BCRs are selected [68]. 
Selected centrocytes then present antigens to Tfh cells through MHC II 
complex and compete for help signals [70]. B cells that survive and 
contain high affinity BCRs exit the GC and become high affinity plasma 
cells or memory B cells [68]. 
 
IV. CD4 T cell responses and MHC class II-restricted 
epitopes study 
 
Naïve CD4 T cells are activated by professional APCs (such as 
dendritic cells) in the T cell zone of secondary lymphoid organs. Activated 
T cells are induced to differentiate into Th1 cells by IFN-γ and IL-12, or into 
Th2 cells by IL-4 [40]. Activated CD4 T cells up-regulate the CD40L 
expression and secret different cytokines, such as IFN-γ and IL-2 from Th1 
cells and IL-4, IL-5 and IL-10 from Th2 cells, to provide help for B cell 
proliferation and immunoglobulin isotypes switching [71, 72]. 
 
APCs process exogenous antigens into small fragments and finally 
present antigenic peptides in the context of MHC (major histocompatibility 
complex) class II molecules [73]. MHC molecules are classified into class I, 
II, III groups and are different in humans and mice called HLA and H-2, 
respectively [74]. MHC class I-restricted epitopes of influenza viruses are 
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better characterized than MHC class II-restricted epitopes of influenza 
viruses in murine models [75].  
 
According to most of published literatures regarding CD4 T cell 
specific epitopes of influenza viruses, epitopes with high frequencies were 
derived from HA and NP [76]. Based on different murine models and virus 
isolates, the source and distribution of CD4 T cell epitopes would vary. In 
C57BL/6 mice after infection of influenza A/HK-x31, a large number of 
MHC class II-restricted epitopes (around 20-30) were unevenly distributed 
within limited proteins, with the majority deriving from NP and HA [75]. 
However, in BALB/c mice, multiple epitopes were also identified in NA of 
x31 viruses [75]. 
 
According to the study involving HLA-DR1 transgenic (DR1 Tg) mice 
and a human influenza isolate A/New Caledonia/20/99 (NC), the repertoire 
of HA-specific CD4 T cells after primary NC infection was very diverse [77]; 
More than 30 epitopes were identified within the entire HA protein, 
including epitopes genetically conserved across H1, H2, and H5 influenza 
viruses [77]. Besides HA, CD4 T cell specific epitopes were also identified 
in NA, NP and NS [77]. 
 
Different hosts express distinct MHC class II molecules, resulting in 
different repertoires of CD4 T cells. The immune response in DR1 Tg mice 
containing a human MHC class II molecule may accurately reflect the 
immune response in humans after natural influenza virus infection. In 
addition to the CD4 T cell response, the B cell response is another 
important component of the adaptive immune response against influenza 
viruses. However, the B cell response in DR1 Tg mice after primary NC 
infection has not been investigated. In this study, our goals were to 
characterize B cell responses after NC infection in DR1 Tg mice and 
 14
establish the correlation of B cell responses with CD4 T cell responses in 
the same mouse model system. 
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CHAPTER 2 
MATERIALS AND METHODS 
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I. Mice 
 
HLA-DR1 transgenic mice were got from Dr. Zaller (Merck) through 
Taconic laboratories and were housed and propagated under 
specific pathogen-free conditions at the animal center of the 
University of Tennessee. Mice were immunized at 2-3 months of 
age and were thereafter kept in BSL-2 containment. 
 
C57BL/10J mice purchased from The Jackson Laboratory were 
housed under specific pathogen-free conditions until immunization 
and thereafter in BSL-2 containment. Female mice were used in all 
experiments and were infected at 8-12 weeks of age. 
 
The Animal Care and Use Committee of the University of 
Tennessee approved all animal procedures. 
 
II. Viruses 
 
Influenza virus A/New Caledonia/20/99 (NC) grown and titrated in 
the allantoic cavity of embryonated hen’s eggs was obtained from 
Dr. Richard Webby (St. Jude Children’s Research Hospital, 
Memphis, TN). Influenza virus A/Puerto Rico/8/1934 (PR8) was 
grown and titrated in the allantoic cavity of embryonated hen’s eggs. 
 
Clone G2.4 of MHV-68 was originally obtained from Dr. A. A. Nash 
(Edinburgh, U.K.), and virus stocks were grown in owl monkey 
kidney cells and titrated on NIH-3T3 cells. 
 
Viruses were inactivated by treatment with ß-propiolactone. Viral 
protein concentrations were measured using the Bio-Rad protein 
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assay kit (Bio-Rad, Hercules, CA). All virus preparations were 
stored at -80 °C 
 
III. Immunization of mice 
 
Mice were anesthetized with Avertin (2,2,2-tribromoethanol) given 
intraperitoneally before all immunizations.  
 
For intranasal (i.n.) infection, mice were infected with 20,000-
40,000 50% egg infectious doses (EID50) of NC, or 25 EID50 of PR8, 
or 104 PFU of MHV-68 (30 µl in PBS).  
 
For intramuscular (i.m.) immunization, a total dose of 20 µg of 
inactivated NC was given in two injections, each of 10 µg (50 µl in 
PBS), into the tibialis anterior muscle of each leg. A plastic sleeve 
over the needle was used to control the depth of injections.  
 
IV. Tissue dissection and treatment 
 
Anesthetized mice were exsanguinated via the retro-orbital plexus 
before organs were collected. Organs were processed to generate 
single-cell suspensions in IMDM media (Invitrogen, Carlsbad, CA) 
containing L- glutamine (2 mM), sodium pyruvate (1 mM), penicillin 
(100 IU/ml), streptomycin (100 µg/ml), gentamicin (10 µg/ml), and 5 
× 10-5 M ß-mercaptoethanol (designated B cell medium), and 
supplemented with 10% FBS. Lymph nodes (CLN, MLN, PLN, IliLN, 
IngLN) and spleens were collected and gently disrupted between 
frosted ends of microscope slides. Bone marrow (BM) cell 
suspensions were obtained by flushing femurs and tibiae. Red 
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blood cells (RBCs) were removed from spleen and BM preparations 
by ammonium chloride lysis. Lungs were perfused with PBS prior to 
collection, and then were finely minced and incubated for 1 hour at 
37 °C in BCM containing 10% FBS and 4 mg/ml collagenase type 
II (Worthington, Lakewood, NJ). Cells pelleted from the lung digest 
were resuspended in 40% isotonic Percoll and layered over 75% 
isotonic Percoll. After centrifugation at 600 × g for 20 min at 25 °C, 
cells at the interface were collected and washed. Lungs to be 
titrated for infectious viruses were homogenized in 1 ml HBSs 
containing antibiotics and 0.1% BSA. Homogenates were clarified 
by centrifugation, and supernatants were collected and stored at -
80°C.  Sera were collected from clotted blood and stored at -80 °C 
for antibody analysis. 
 
V. ELISPOT assay 
 
A preparation of concentrated viral particles was disrupted for 10 
min at room temperature in a 1 in 10 dilution of disruption buffer 
(0.5% Triton X-100, 0.6 M KCl, and 0.05 M Tris-HCl, pH7.5) in PBS, 
further diluted in PBS, and plated at 1 µg/well in nitrocellulose-
bottomed 96-well MultiScreen HA filtration plates (Millipore, Bedford, 
MA). After overnight incubation at 4°C, plates were washed with 
PBS, and then were blocked with BCM containing 10% FBS for 1 
hour. Plates were emptied by flicking, and were washed with PBS. 
Single-cell suspensions were then added to plates in a volume of 
100 µl/well. After incubation for 3-4 hours at 37°C in a humidified 
atmosphere containing 5% CO2, plates were thoroughly washed 
with PBS alone and PBS containing 0.1% Tween 20.  Alkaline 
Phosphatase-conjugated Goat Anti-Mouse IgGs, IgM, IgA 
(Southern Biotechnology, Birmingham, AL) diluted to 2 µg/ml in 
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PBS containing 5% BSA were added to plates in a volume of 100 
µl/well, and plates were then incubated overnight at 4°C. Plates 
were washed thoroughly with PBS alone and PBS containing 0.1% 
Tween 20, including washing the underside of the nitrocellulose 
filter. Spots were developed at room temperature by adding 100 
µl/well of 1 mg/ml of 5-bromo-4-chloro-3-indolylphosphate (Sigma, 
St. Louis, MO) in diethanolamine buffer (10% diethanolamine, 0.1 
M NaCl, 5 mM MgCl2, and 0.1 M Tris-HCl, pH 9.5). After optimal 
spots development, plates were washed with PBS and dried at 
room temperature. Spots representing individual antibody secreting 
cell (ASC) were counted using an Olympus SZX9 stereozoom 
microscope. 
 
VI. ELISA 
 
A preparation of concentrated viral particles was disrupted for 10 
min at room temperature in a 1 in 10 dilution of disruption buffer 
(0.5% Triton X-100, 0.6 M KCl, and 0.05 M Tris-HCl, pH 7.5) in 
PBS, further diluted in PBS, and plated at 0.5 µg/well in 96-well flat 
bottom immuno plates (Nalge Nunc International, Rochester, NY) in 
a volume of 50 µl/well. After overnight incubation at 4°C, plates 
were washed with PBS containing 0.05% Tween 20, and were 
blocked with PBS containing 3% BSA for at least 90 min in a 
volume of 150 µl/well at room temperature. Plates were emptied by 
flicking, and were washed with PBS containing 0.05% Tween 20. 
Serum samples were serially 3-fold diluted in PBS containing 0.5% 
BSA and 0.05% Tween 20, and were added to plates in a volume 
of 50 µl/well. Plates were incubated for 3-4 hours at room 
temperature or overnight at 4°C, and then were washed with PBS 
containing 0.05% Tween 20. Alkaline Phosphatase-conjugated 
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Goat Anti-Mouse Abs with specificities for IgGs, IgA, IgM or Ig (H+L) 
(Southern Biotechnology, Birmingham, AL) diluted in PBS 
containing 1% BSA were added in a volume of 100 µl/well, and 
plates were incubated for 2-4 hours at room temperature or 
overnight at 4°C. After plates were washed with PBS containing 
0.05% Tween 20, color was developed by adding 5 mg/15ml of p-
nitrophenyl phosphate substrate (Sigma, St. Louis, MO) in 
diethanolamine buffer (10% diethanolamine, 0.1 M NaCl, 5 mM 
MgCl2, and 0.1 M Tris-HCl, pH 9.5) in a volume of 100 µl/well at 
room temperature for 20-30 min. Absorbance was measured at 405 
nm in the Synergy 2 multi-Detection Microplate Reader using Gen5 
software (Biotek). Titers of virus-specific Abs were determined as 
the reciprocal of the highest dilution giving an absorbance value 
larger than 0.1 and at least two-fold higher than the absorbance of 
simultaneously titrated naïve samples. 
 
VII. Virus titration 
 
Viral titers in lung homogenates were determined by 50% tissue 
culture infection dose (TCID50) using Madin-Darby Canine Kidney 
(MDCK) cells grown in MEM medium (Invitrogen, Carlsbad, CA) 
containing L- glutamine (2 mM), penicillin (100 IU/ml), streptomycin 
(100 µg/ml), gentamicin (10 µg/ml), and supplemented with 5% 
FBS. Confluent cell monolayer in a 96-well tissue culture plate was 
washed twice with FBS-free MEM medium containing 0.3% BSA 
immediately before the transfer of viral inocula. Serial 10-fold 
dilutions of lung homogenates were prepared on a 96-well round 
bottom polypropylene plate (Corning Incorporated, Corning, NY). 
Add 225 µl of MEM containing L- glutamine (2 mM), penicillin (100 
IU/ml), streptomycin (100 µg/ml), gentamicin (10 µg/ml), 0.3% BSA 
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and 2 µg/ml L-(tosylamido-2-phenyl) ethyl chloromethylketone 
(TPCK) -treated Trypsin (Worthington, Lakewood, NJ) (designated 
VGM) to every well. Add 25 µl of lung homogenates to the first well 
of each row. Mix and transfer 25 µl to successive wells to generate 
10-fold dilutions. Transfer 200 µl of lung homogenate dilutions to 
corresponding wells of the washed MDCK cells plate. After 2-3 
days incubation at 37°C in a humidified atmosphere containing 5% 
CO2, observe the plate under an inverted microscope for viral CPE, 
and draw 50 µl/well of supernatants to perform HA assay. Calculate 
the TCID50 by the Reed-Muench method.  
 
VIII. Hemagglutination assay (HA) 
 
Orient a 96-well round bottom polystyrene assay plate (Corning 
Incorporated, Corning, NY) so that samples will be diluted 12 wells 
across. Number the row on each plate to identify different samples. 
Add 50 µl PBS to every well on the plate. Add virus suspensions or 
cell culture supernatants to the first well in each row in a volume of 
50 µl. Note that this will result in a 1:2 dilution of the test sample in 
the first well. A positive control and a negative control (such as PBS 
only) must be included. Mix the content of the first well by pipetting 
up and down 10 times and transfer 50 µl to successive wells to 
make 2-fold dilutions of the sample across the entire row. Discard 
the final 50 µl after the last row. At this point every well should have 
a volume of 50 µl.  Add 50 µl of 0.5% chicken red blood cells 
(RBCs) suspension (Fitzgerald, Concord, MA) to every well. Mix the 
plate by using a mechanical vibrator or by taping the plate gently. 
Incubate the plate at room temperature for an appropriate time (30-
60 min) by checking negative control wells for complete settling of 
RBCs. 
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Results of the HA assay should be interpreted when RBCs in 
negative control wells had settled down to form solid buttons at the 
bottom of wells (hemagglutination-negative). When the plate was 
tilted at approximate 45-degree, RBCs in negative control wells 
would stream down in a “tear-drop” fashion. Samples that were 
hemagglutination-negative should also form solid buttons at the 
bottom of wells and slide down at the same rate as negative 
controls. Samples showing complete hemagglutination in one or 
more wells were considered hemagglutination-positive. Incomplete 
hemagglutination was observed as buttons that did not slide, had 
fuzzy margins, or formed a doughnut-shaped ring at the bottom of 
wells. The endpoint of a sample was the highest dilution causing 
complete hemagglutination. The endpoint dilution was considered 
containing one hemagglutination unit (HAU), and the number of 
HAUs/50 µl was the reciprocal of the highest dilution. 
 
IX. Hemagglutination inhibition assay (HAI) 
 
a. Treatment of sera 
 
Sera against influenza viruses prepared in most animals 
(ferret, rabbit, mouse) must be treated with receptor 
destroying enzyme (RDE) to eliminate nonspecific 
hemagglutination inhibitors. RDE (II) “SEIKEN” (Denka 
Seiken CO. LTD, Tokyo, Japan) was completely dissolved in 
20 ml of sterile physiological saline, 0.85% NaCl. This 
solution should be used immediately or be aliquot and stored 
at - 20°C or less. Under sterile condition add 3 vols of RDE 
to 1 vol of sera (such as 90 µl RDE + 30 µl sera), and mix 
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thoroughly. Heat the mixture in a 37°C waterbath for 18-20 
hours to allow the reaction to occur. Then heat the mixture in 
a 56°C waterbath for 30-60 min to inactivate remaining RDE. 
Allow the mixture to cool down to room temperature. Add 6 
vols of sterile physiological saline, 0.85% NaCl (such as 180 
µl). The final dilution of the sera was 1:10. 
 
b. HA titration of the control antigen 
 
The control antigen was titrated by following the procedure 
of hemagglutination assay described above. The endpoint of 
a sample was the highest dilution causing complete 
hemagglutination. The endpoint dilution was considered 
containing one hemagglutination unit (HAU), and the number 
of HAUs/50 µl was the reciprocal of the highest dilution. 
Calculate the HAUs/50 µl of the control antigen. 
 
c. Preparation of standardized antigens for HAI and “Back 
titration” 
 
Standardized antigens used for HAI should have 4 HAUs/25 
µl or 8 HAUs/50 µl. Calculate the antigen dilution by dividing 
the HAUs/50 µl of the control antigen by 8 in order to get 8 
HAUs/50 µl of standardized antigens. Make the dilution in an 
appropriate volume. 
 
The “back titration” was performed by doing HA assay to 
verify the 8 HAUs/50 µl of standardized antigens. Add 50 µl 
PBS to well #1-6 on a 96-well microtiter plate. Add 50 µl 
standardized antigens (8 HAUs/50 µl) to well #1. Mix and 
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transfer 50 µl to successive wells to make serial 2-fold 
dilutions until well #6. Discard the final 50 µl. Each well 
should contain 50 µl after this step. Add 50 µl 0.5% RBCs to 
each well. Mix the plate by using a mechanical vibrator or 
taping gently. Incubate the plate at room temperature for 30-
60 min to allow RBCs to settle down at the bottom of wells. 
The first three wells should be hemagglutination-positive. 
Store standardized antigens at 4°C and use within the same 
day. 
 
d. Hemagglutination inhibition (HAI) 
 
Orient a 96-well round bottom polystyrene assay plate 
(Corning Incorporated, Corning, NY) so that samples will be 
diluted 8 wells across. Add 25 µl PBS to wells of row B 
through G (B1-G12). Add 50 µl RDE-treated samples (1:10) 
to wells of row A (A1-A12) and add 25 µl the same RDE-
treated samples (1:10) to wells of row H (H1-H12) as well. 
Prepare serial 2-fold dilutions of treated samples by 
transferring 25 µl from row A to successive wells until row G. 
Discard the final 25 µl after row G. Add 25 µl standardized 
antigens to wells of row A through G (A1-G12). Add 25 µl 
PBS instead of standardized antigens to wells of row H (H1-
H12). Mix the plate by using a mechanical vibrator or taping 
gently. Incubate the plate at room temperature for 1 hour. 
Add 50 µl 0.5% RBCs to every well, and mix as before. 
Incubate the plate at room temperature for an appropriate 
time for RBCs settling. The HAI titer was the reciprocal of the 
highest dilution of the sample that completely inhibited 
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hemagglutination of standardized antigens. Record HAI titers 
of samples. 
 
X. Neutralization assay 
 
a. Preparation of test samples 
 
Sera samples were treated with RDE as described above in 
HAI assay. Orient a 96-well round bottom polypropylene 
assay plate (Corning Incorporated, Corning, NY) so that 
samples would be diluted 12 wells across. Add 60 µl VGM to 
wells of column 2 through 12. Add 120 µl the RDE-treated 
sample (1:10) to the first well of each row. Prepare serial 2-
fold dilutions by transferring 60 µl from the first well to 
successive wells until column 12 and discard the final 60 µl. 
Each well should contain 60 µl sample dilutions after this 
step. 
 
b. Addition of standardized viruses and “back titration” 
 
Standardized viruses contain 50 TCID50/50 µl in VGM. Add 60 
µl standardized viruses to each well except cell control wells. 
Add 60 µl VGM instead of standardized viruses to cell control 
wells. 
 
Set up “back-titration” as follows on a separate 96-well round 
bottom polypropylene assay plate. This required 
quadplications of ½ lg dilutions of standardized viruses. Add 
120 µl VGM to wells of column 2 through 8, and then add 175 
µl standardized viruses (50 TCID50/50 µl) to the first column. 
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Generate ½ lg dilutions by transferring 55 µl from the first well 
to successive wells. Discard the final 55 µl.  
 
Plates containing sample/virus mixture, virus back-titration and 
cell controls were gently agitated and incubated at 37°C in a 
humidified atmosphere containing 5% CO2 for 2 hours. 
 
c. Inoculation of MDCKs and HA assay 
 
During the final 15-30 min of the incubation period, wash 
confluent MDCK monolayers in 96-well cell culture plates 
with 200 µl/well MEM containing 0.3% BSA twice. After the 
completion of 2 hours incubation period of sample/virus 
mixtures, empty the last wash of MDCK monolayers, and 
transfer 100 µl/well sample/virus mixtures to corresponding 
wells in MDCK cell plates. Change tips for each transfer. 
Add 100 µl VGM to each well to bring the final volume in 
MDCK plates to 200 µl/well. Incubate MDCK plates at 37°C 
in a humidified atmosphere containing 5% CO2 for 2-3 days. 
Then draw 50 µl/well supernatants to perform HA assay. The 
neutralizing Abs titer of the sample was the reciprocal of the 
highest dilution of the sample that completely prevented 
virus infection of MDCK cells. 
 
XI. Cell surface staining and flow cytometry 
 
Single-cell suspensions from lymph nodes (CLN, MLN) and spleens 
were stained as follows. Add 1 × 106 cells to designated wells of a 
96-well round bottom plate. Centrifuge the plate at 1500 rpm for 5 
min at room temperature. Flick off the supernatant and vortex the 
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plate to resuspend cells. Block cells with 100 µl/well Fc blocking 
antibody or normal naïve mice serum diluted 1/200 or 1/100, 
respectively, in PBS containing 2% FBS and 0.05% sodium azide 
(FACS buffer). Cells were resuspended thoroughly and incubated 
on ice for 30 min. Centrifuge the plate as before, flick off the 
supernatant and vortex the plate to resuspend cells. Dilute primary 
antibodies 1/200 in FACS buffer, and add to appropriate wells in a 
volume of 100 µl/well and mix thoroughly. For the unstained well, 
add 100 µl of PBS instead of primary antibody dilution. Wrap the 
plate with foil and incubate the plate on ice for 30 min. Centrifuge 
the plate as before, flick off the supernatant and resuspend cells 
with 100 µl/well FACS buffer. Transfer cell suspensions to 5 ml 
polystyrene round bottom tubes (Becton Dickinson, Franklin Lakes, 
NJ). Add 600 µl of FACS buffer to each tube. Keep samples on ice 
and covered until ready to run using FACScan and Cellquest 
software. For the analysis of germinal center B cell differentiation, 
cells were stained with PE-conjugated anti-Fas, PerCP-conjugated 
anti-B220 (BD Biosciences), and FITC-conjugated-Peanut 
agglutinin (PNA) (Vector Laboratories. Inc., Burlingame, CA). 
 
XII. Statistics 
 
Statistical comparisons of mean values were performed using the 
unpaired T test for unpaired samples. Values of p < 0.05 were 
considered statistically significant. 
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RESULTS 
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I.   B cell responses in HLA-DR1 transgenic mice and C57BL/10J 
mice after intranasal infection of influenza virus NC 
 
a. Kinetic analyses of influenza-specific Abs responses to intranasal 
administration of influenza virus NC 
 
To explore influenza-specific ASCs responses in DR1 Tg 
mice, naïve mice were infected with NC intranasally, and draining 
lymph nodes, spleens, BMs and lungs were collected at different 
time intervals post-infection. B10 mice were included to compare 
with DR1 Tg mice in this experiment. The kinetics of NC-specific 
ASCs responses in CLNs, MLNs, spleens, BMs and lungs were 
showed in Fig. 1. On day 8 after virus infection, the virus-specific 
response in the MLN of B10 mice slightly preceded responses in 
the MLN of DR1 Tg mice, suggesting in DR1 Tg mice the humoral 
response was delayed by some factors. In DR1 Tg mice, peak 
numbers of virus-specific ASCs showed up in the CLN, MLN, and 
spleen subsequent to 2 weeks after infection and progressively 
decreased from 2 to 3 weeks after infection. The virus-specific 
ASCs response in DR1 Tg mice was characterized by predominant 
IgG1 isotype switching, which was not observed in B10 mice. 
Virus-specific ASCs appeared in the BM and lung between 2 and 3 
weeks after influenza infection, and IgG1 was the predominant 
switched isotype in DR1 Tg mice which was consistent with ASCs 
isotype profiles in draining LNs and spleens. 
 
Levels of virus-specific Abs in sera closely reflected the 
single cell analysis of the B cell response (Fig. 2). In DR1 Tg mice, 
the titer of IgG1 was higher than other isotypes, and titers of all 
isotypes were lower on day 8 than that of B10 mice. Regardless of 
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different isotypes, the titer of virus-specific Ig in sera was lower in 
DR1 Tg mice compared to B10 mice on days 8 and 10 after 
infection, reflecting the delayed B cell response in DR1 Tg mice 
(Fig. 3, A). The neutralization assay was conducted to measure 
the titer of neutralizing Abs. DR1 Tg mice showed significantly 
higher neutralizing Abs titers than B10 mice (p < 0.05) on day 14 
after infection. Also DR1 Tg mice demonstrated stronger 
hemagglutination inhibition activity than B10 mice on day 14 after 
infection (p < 0.05). Taken together, the acute immune response 
following i.n. NC infection was skewed towards the IgG1/Th2 bias 
with higher neutralizing Abs titers and HAI titers in DR1 Tg mice. 
 
The kinetics of the viral growth was determined by TCID50 
using lung homogenates of infected mice (Fig. 4). At early time 
points after infection there was no difference between DR1 Tg 
mice and B10 mice. However, on day 10 viruses were still 
detectable in DR1 Tg mice but became cleared in B10 mice, 
suggesting that virus clearance was slower in DR1 Tg mice 
compared to B10 mice. 
 
b. Germinal center formation and the comparison of influenza-specific 
and non-specific ASCs responses after intranasal administration of 
influenza virus NC 
 
Based on the intriguing observation of the IgG1/Th2 bias and 
higher neutralizing Abs titers in DR1 Tg mice, we analyzed the GC 
reaction in MLNs after i.n. NC infection in DR1 Tg mice and B10 
mice. We identified by flow cytometry a distinct population of 
germinal center B cells, stained with anti-B220 and anti-Fas 
monoclonal antibodies and the peanut agglutinin (PNA), in both 
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DR1 Tg mice and B10 mice. In DR1 Tg mice, percentages of 
germinal center B cells (B220+PNAhiFashi) in MLNs were similar 
with B10 mice on days 8,10, and 14, but higher than B10 mice on 
day 21 (Fig. 5, A). When we compared frequencies of germinal 
center B cells per lymph node, there was no difference between 
two groups (Fig. 5, B). But if the frequency of germinal center B 
cells were calculated per 106 lymphocytes or per 105 B-
lymphocytes, significant difference was showed on day 21 after 
infection (Fig. 5, C-D).  
 
Previous studies suggested that strong early polyclonal B cell 
activation competed with virus-specific B cell activation and the 
formation of neutralizing Abs [78]. Virus-specific and non-virus-
specific ASCs frequencies in MLNs were determined after i.n. NC 
infection in DR1 Tg mice and B10 mice. Since the immune 
response was delayed in DR1 Tg mice, the non-specific response 
also started later on day 10 post infection, with IgG1 predominating 
and minimal other isotypes (Fig. 6). The non-specific ASC 
response in DR1 Tg mice was weaker compared with the massive 
non-specific B cell response in B10 mice at early stage.  In B10 
mice, total ASCs numbers peaked on day 8 post-infection and 
decreased gradually on day 10 and 14. And isotype profiles of 
virus-specific and total ASCs responses were similar showing 
switched IgG2c bias in B10 mice (Fig. 6).  
 
 
II.   B cell responses in HLA-DR1 transgenic mice and C57BL/10J 
mice after intramuscular immunization of influenza virus NC 
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Puzzled by the IgG1/Th2 bias in DR1 Tg mice after i.n. NC 
infection, we wondered whether it was a characteristic of immune 
responses of DR1 Tg mice. We immunized DR1 Tg mice and B10 
mice with inactivated NC intramuscularly and collected draining 
LNs and spleens to determine virus-specific ASCs frequencies on 
days 8 and 11 post immunization.  Isotype profiles were strikingly 
similar between DR1 Tg mice and B10 mice, characterized by IgM 
predominance in the IngLN, IliLN, and spleen on day 8 and 
predominant IgG2c isotype switching on day 11 (Fig. 7). In DR1 Tg 
mice the observed predominance of switched IgG1 after i.n. NC 
infection was replaced by the IgG2c bias after i.m. administration. 
 
 
III. B cell responses in HLA-DR1 transgenic mice and C57BL/10J 
mice after intranasal infection of influenza virus PR8 
 
Since the i.m. vaccination induced a different isotype profile 
of B cell responses in DR1 Tg mice, we tested a different influenza 
virus isolate to see whether the immune response profile could be 
different. In this experiment, mice were infected with PR8 (H1N1) 
intranasally. In contrast to i.n. NC infection, PR8 infection induced 
earlier and stronger B cell responses in DR1 Tg mice, with 
massive IgM production starting on day 6 and peaking on day 8 (~ 
20-fold of that of NC infection). Then the early peak of virus-
specific IgM ASCs gave way to increased numbers of cells 
producing IgG isotypes, particularly IgG3 (Fig. 8, B). Compared 
with i.n. NC infection, PR8 infection obviously did not modify the 
isotype profile of B cell responses in B10 mice (Fig. 8, A), showing 
the same IgG2c predominance. Serum levels of virus-specific Abs 
also reflected the single cell analysis of B cell responses (Fig. 9). 
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And DR1 Tg mice showed higher neutralizing Abs titers than B10 
mice on day 10 after PR8 infection (Fig. 10, A). 
 
Influenza virus PR8 is a mouse-adapted strain, while NC has 
not been adapted to grow in mice. So we wondered whether the 
virus replication was different between the two strains. The viral 
load in the lung after i.n. PR8 infection was measured by TCID50 
using lung homogenates. There was no significant difference on 
viral titers between DR1 Tg mice and B10 mice on days 6, 8, and 
10 after PR8 infection (Fig. 10, B). And when we compared the 
viral titer between i.n. NC infection and i.n. PR8 infection on day 8 
in DR1 Tg mice and B10 mice, respectively, no difference was 
observed (data not shown). However, because the infection dose 
of NC was ~ 400 fold of PR8, it was obvious that PR8 replicated 
better than NC in mice. Therefore, although viral titers in the lung 
were similar on day 8 after NC and PR8 infection, the better PR8 
virus replication in the lung may induce different cytokines 
production and resulted in different B cell immune responses. 
 
 
IV. B cell responses in HLA-DR1 transgenic mice and C57BL/10J 
mice co-infected with NC and MHV-68 viruses intranasally 
 
Previous studies showed i.n. MHV-68 infection mainly induced 
the IgG2a/IgG2b production with a low level of IgG1 production [79].  
So we were interested in whether the Th2 biased B cell response in 
DR1 Tg mice following i.n. NC infection could be altered by a co-
infection with MHV-68, which is a Th1 biased virus. In this 
experiment, co-infected mice were sampled on days 8 and 10 after 
co-infection and MLNs were collected to conduct ELISPOT assay 
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to enumerate NC-specific and MHV-68-specific ASCs, respectively. 
In both DR1 Tg mice and B10 mice, MHV-68-specific IgM ASCs 
peaked on day 8 and was followed by increased IgGs isotypes 
switching, especially the IgG2c (Fig. 11, B and D). The kinetics and 
isotype profiles of NC-specific B cell responses were similar in co-
infected DR1 Tg mice and B10 mice, demonstrating a IgG2c biased 
immune response. However, the co-infection induced different NC-
specific ASCs responses in DR1 Tg mice compared with i.n. NC 
infection. The NC-specific ASCs response was changed to Th1 
bias in co-infected DR1 Tg mice, with IgG2c predominating (Fig. 11, 
A and C), meanwhile the i.n. NC infected DR1 Tg mice still 
displayed Th2 biased responses with IgG1 predominance. Overall, 
the co-infection of MHV-68 and NC viruses successfully switched 
the NC-specific humoral response from a Th2 bias to a Th1 bias in 
DR1 Tg mice. The mechanism behind this observation was still 
unclear.   
 
The dispersion of different isotypes of circulating NC-specific 
Abs in sera also reflected the ASCs response. Isotype profiles were 
similar after co-infection between DR1 Tg mice and B10 mice, 
showing higher NC-specific IgG2c production than IgG1 (Fig. 12, A-
D).  But neutralizing Abs titers were below the limit of measurement 
in both groups. Since the NC-specific immune response was 
changed by co-infection with MHV-68 virus compared with i.n. NC 
infection, we wanted to know whether the virus replication in the 
lung was also changed. By comparing virus titers between NC-only 
infection and co-infection groups on day 8, no significant difference 
was observed. 
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Figure legend 
 
Fig. 1 The primary influenza-specific ASCs response to intranasal 
administration of NC in DR1 Tg mice and B10 mice. The kinetics of virus-
specific ASC responses in the CLN (A), MLN (B), spleen (C), lung (D) and 
BM (E) were determined in mice infected with NC intranasally. The 
ELISPOT assay was used to enumerate virus-specific ASCs in single cell 
suspensions from individual mouse. Results were expressed as the 
number of ASCs/105 nucleated cells or the number of ASCs/5x105 
nucleated cells. CLN, cervical lymph node; MLN, mediastinal lymph node; 
BM, bone marrow. Data were mean + SE (n > 3). 
 
Fig. 2 The influenza-specific Abs level in serum after intranasal 
administration of NC in DR1 Tg mice and B10 mice. The kinetics of virus-
specific Abs titers of different isotypes, IgG1 (A), IgG2b (B), IgG2c (C), 
IgG3 (D), IgM (E), IgA (F), were measured by ELISA. Results were 
determined by endpoint titration and did not necessarily reflect the relative 
amount of each isotype. Data were mean + SE (n > 3). 
 
Fig. 3 The influenza-specific immunoglobulin level and neutralizing Abs 
titers and hemagglutination inhibition titers in serum after intranasal 
administration of NC in DR1 Tg mice and B10 mice. (A) The kinetics of 
virus-specific Ig was measured by ELISA and results were determined by 
endpoint titration. (B) Neutralizing Abs titers in serum were measured by 
neutralization assay. Results were expressed as the reciprocal of the 
highest serum dilution completely preventing virus infection of MDCK cells. 
(C) HAI titers in serum were measured by hemagglutination inhibition 
assay and results were expressed as the reciprocal of the highest serum 
dilution completely inhibiting hemagglutination activity of standardized 
viruses.  
 36
 
Fig. 4 Virus replication in the lung after intranasal infection of NC in DR1 
Tg mice and B10 mice. Lungs of infected mice were collected at different 
time intervals post-infection. Lung homogenates were used to perform 
TCID50. Viral titers were determined by endpoint dilution that infected 50% 
MDCK cells. Results were expressed as log10TCID50 / 0.2 ml lung 
homogenates. Data were mean + SE (n > 3). 
 
Fig. 5 Germinal center formation in the MLN of DR1 Tg mice and B10 
mice after i.n. NC infection. Lymphocytes were isolated and analyzed on 
days 8, 10, 14 and 21 after infection. (A) Flow cytometry of germinal 
center B cells in the MLN. Gated B220+ B cells were shown. PNAhiFashi 
germinal center B cells were boxed, with the percentage of B220+ B cells 
indicated. (B) The number of germinal center B cells (B220+PNAhiFashi) 
per MLN. (C-D) Frequencies of germinal center B cells expressed as the 
number of B220+PNAhiFashi per 106 lymphocytes or 105 B220+ cells, 
respectively. MLN, mediastinal lymph node. Data were mean + SE (n > 3). 
 
Fig. 6 Comparison of influenza-specific and non-specific ASCs responses 
in the MLN of DR1 Tg mice and B10 mice following intranasal infection of 
NC. MLNs were collected from infected mice on days 10 (A) and 14 (B) 
after infection. The ELISPOT assay was used to enumerate ASCs in 
single cell suspensions from individual mouse. Purified NC viruses and 
goat anti-mouse Abs were used to coat ELISPOT plates, respectively. 
Results were expressed as the number of ASCs/105 nucleated cells. MLN, 
mediastinal lymph node. 
 
Fig. 7 The primary influenza-specific ASCs response to intramuscular 
administration of inactivated NC in DR1 Tg mice and B10 mice. Mice were 
sampled at days 8 and 10 after i.m vaccination with inactivated NC. 
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IngLNs (A), IliLNs (B), and spleens (C) were collected on day 8 and PLNs 
(D), IliLNs (E) and spleens (F) were collected on day 10. The ELISPOT 
assay was used to enumerate virus-specific ASCs in single cell 
suspensions from individual mouse. Results were expressed as the 
number of ASCs/5x105 nucleated cells. IngLN, inguinal lymph node; IliLN, 
iliac lymph node; PLN, popliteal lymph node. Data were mean + SE (n > 3). 
 
Fig. 8 The influenza-specific ASCs response to intranasal administration 
of influenza virus PR8 in DR1 Tg mice and B10 mice. MLNs of B10 mice 
(A) and DR1 Tg mice (B) were collected and processed into single cell 
suspensions on days 6, 8 and 10 after i.m. immunization. The ELISPOT 
assay was used to enumerate PR8-specific ASCs from individual mouse. 
Results were expressed as the number of ASC/105 nucleated cells. MLN, 
mediastinal lymph node. Data were mean + SE (n > 3). 
 
Fig. 9 Influenza-specific Abs levels in serum after intranasal infection of 
PR8 in DR1 Tg mice and B10 mice. The kinetics of virus-specific Abs 
titers of different isotypes, IgG1 (A), IgG2b (B), IgG2c (C), IgG3 (D), IgM 
(E), and IgA (F), were determined by ELISA. Results were determined by 
endpoint titration and did not necessarily reflect the relative amount of 
each isotype. Data were mean + SE (n > 3). 
 
Fig. 10 Neutralizing Abs titers in serum and viral growth in the lung after 
intranasal infection of PR8 in DR1 Tg mice and B10 mice. (A) Neutralizing 
Abs titers in serum were determined by neutralization assay. Results were 
expressed as the reciprocal of the highest dilution of the serum completely 
preventing virus infection of MDCK cells. (B) Lung homogenates of 
infected mice were used to perform TCID50 to measure the virus growth in 
lungs. Viral titers were determined by endpoint dilution that infected 50% 
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MDCK cells. Results were expressed as log10TCID50 /0.2 ml lung 
homogenates. 
 
Fig. 11 Influenza-specific ASCs responses in mice co-infected with NC 
and MHV-68 viruses. DR1 Tg mice and B10 mice were intranasally 
infected by NC and MHV-68 viruses. MLNs were collected on days 8 (A-B) 
and 10 (C-D) post-infection. The ELISPOT assay was used to enumerate 
virus-specific ASCs from individual mouse. Purified NC viruses and 
purified MHV-68 viruses were used to coat ELISPOT plates to measure 
NC-specific ASCs (A, C) and MHV-68-specific ASCs (B, D), respectively. 
Results were expressed as the number of ASCs/105 nucleated cells. MLN, 
mediastinal lymph node.  
 
Fig. 12 Influenza-specific Abs levels in serum of mice co-infected with NC 
and MHV-68 viruses. Titers of different NC-specific isotypes (A-D) and 
NC-specific immunoglobulin (E) were determined by ELISA. Results were 
determined by endpoint titration and did not necessarily reflect the relative 
amount of each isotype. (F) Comparison of viral titers in lungs between 
NC-only and co-infected mice on day 8. Virus titers were determined by 
endpoint dilution that infected 50% MDCK cells. Results were expressed 
as log10TCID50 / 0.2 ml lung homogenates. 
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DISCUSSION 
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The transgenic mouse model system used in this study contains a 
human MHC class II molecule HLA-DR1 [80-82] and provides a useful 
model for evaluating the diversity and specificity of CD4 T cell responses 
that may develop in humans following influenza virus infection or 
vaccination [77, 83]. The influenza virus A/New Caledonia/20/99 (NC) 
used in the study is not a mouse-adapted isolate and has been circulating 
in the North American human populations for more than 10 years [84]. The 
influenza-specific B cell response to intranasal administration (i.n.) of NC 
was analyzed in HLA-DR1 transgenic mice (DR1 Tg) and in the 
genetically matched H-2b strain C57BL/10J (B10). The B cell ELISPOT 
assay was used to characterize the production of virus-specific ASCs at 
the single cell level.  In B10 mice, the B cell response in draining LNs was 
typical of previously described B cell responses to a variety of mouse-
adapted influenza viruses, characterized by a Th1 bias, as indicated by a 
stronger IgG2c production. In contrast, the B cell response in DR1 Tg 
mice followed delayed kinetics and was strongly skewed to a Th2 bias, as 
indicated by a stronger IgG1 production. This phenomenon was observed 
in draining LNs and spleens. Another interesting feature of the B cell 
response to NC infection in DR1 Tg mice was that there were higher 
neutralizing Abs titers and hemagglutination inhibition (HAI) titers on day 
14 after virus infection compared with B10 mice. 
 
However, the IgG1/Th2 bias was not a characteristic of all B cell 
responses in DR1 Tg mice. After intramuscular vaccination of inactivated 
NC, the virus-specific B cell response displayed a strong IgG2c/Th1 bias 
instead of the IgG1 skewing in draining LNs and spleens. This feature was 
also evident when PR8 (H1N1 isolate) was given intranasally. The PR8-
specific B cell response after intranasal infection demonstrated a totally 
different isotype profile, demonstrating a massive PR8-specific IgM/IgG3 
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production. The virus-specific IgG1 skewing which was evident after i.n. 
NC infection in DR1 Tg mice was also abolished. Based on these 
observations, we concluded that the unusual IgG1/Th2 bias was restricted 
to the intranasal infection of NC in DR1 Tg mice.  
 
Additional experiments were conducted to probe the mechanism 
behind the NC-specific IgG1/Th2 bias in DR1 Tg mice. Murine 
gammaherpesvirus 68 (MHV-68) is a member of the γ-herpesvirus family, 
that infects epithelial cells and mononuclear cells in the lower respiratory 
tract [85]. A previous study showed that MHV-68-specific B cell responses 
after i.n. infection were characterized by a predominant IgG2a/IgG2b 
ASCs production and a low level of IgG1 production [79]. Therefore, we 
speculated that the Th2 biased B cell response in DR1 Tg mice following 
i.n. NC infection could be altered by a co-infection with MHV-68, which is a 
Th1 biased virus. Our data demonstrated that in co-infected DR1 Tg mice, 
the IgG1 biased NC-specific B cell response in draining LNs was 
abolished. Instead, the isotype profile skewed towards the IgG2c/Th1 bias. 
Notably, the MHV-68-specific response did not change as a result of the 
co-infection. The mechanism underlying this observation was still not clear. 
 
The current study raised several questions, such as what factors 
drove the antibody isotype switching to IgG1 in DR1 Tg mice after i.n. NC 
infection, and why the neutralizing Abs titer and the HAI titer were higher 
although the titer of virus-specific immunoglobulin in serum was lower in 
DR1 Tg mice compared to B10 mice. The B cell activation is dependent 
on help signals received from CD4 T cells, and the priming of CD4 T cells 
relies on antigen presentations by professional APCs, especially infected 
dendritic cells (DCs) [86-88]. We speculated that the antigen presentation 
process after influenza virus infection contributed to these observations in 
DR1 Tg mice. The high level synthesis of viral proteins within infected DCs 
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could override some factors that usually restrict the presentation of 
endogenous peptides by MHC class II molecules, resulting in broader 
diversity of CD4 T cell specific repertoire [77]. Also higher numbers of 
antigen-bearing DCs in lymph nodes after influenza virus infection can 
help diversify the CD4 T cell specific repertoire by reducing the 
competition for antigens [89]. After intranasal infection, NC can replicate 
better in infected epithelial cells and DCs; but after intramuscular 
vaccination, NC lose the access to replicate in these cells. Therefore, 
antigen presentations by DCs after i.n. and i.m. could be quite different, 
resulting in distinct CD4 T cells priming and the down-stream B cell 
activation. In vitro studies have indicated that the up-regulated expression 
of MHC class II molecules and co-stimulatory molecules, like CD40 and 
OX40L, on activated DCs mediated Th2 differentiation [90, 91]. Current 
studies focusing on the CD4 T cell specific repertoire after NC virus 
infection showed a much broader distribution of CD4 T cells specific 
epitopes in DR1 Tg mice, while previous studies identified restricted CD4 
T cell specific repertoire in C57BL/6 mice [75, 77, 83]. The CD4 T cell 
specific repertoire in B10 after NC primary infection was revealed to be 
narrow and was limited to certain proteins. 
 
Besides different diversities of the CD4 T cell repertoire between 
DR1 Tg mice and B10 mice, different specificities of CD4 T cells may also 
play an important role in the immune response. One hypothesis underlying 
the current project is that B cells display a limited subset of influenza-
derived peptides specificities that are mainly restricted to antigens from 
HA, NA and M2. The specificity of CD4 T cells that help Ag-specific B cells 
to produce neutralizing antibodies in vivo after influenza infection is largely 
restricted to these peptides derived from HA, NA and M2, especially the 
HA [83].  The remaining CD4 T cells with specificities for internal viral 
antigens may be counterproductive to the protective immunity by 
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occupying needed “space” in the CD4 T cell memory compartment [83]. T 
cells and B cells with the same specificity can form long-lasting cognate 
interactions which ensure B cells get essential and enough help signals to 
undergo further differentiation, immunoglobulin isotype switching and 
affinity maturation [92, 93]. Studies done by our collaborating lab at the 
University of Rochester (Andrea Sant’s lab) demonstrated that the 
repertoire of HA-specific CD4 T cells after primary influenza infection in 
DR1 Tg mice was very broad, containing more than 30 different 
specificities within the entire HA [77]. However, in B10 mice, the majority 
of CD4 T cell-specific epitopes were derived from NP and NA [94]. 
Therefore, the diverse HA-specific CD4 T cells in DR1 Tg mice would be 
more effective in activating HA-specific B cells and facilitating the 
neutralizing Abs production. On the other hand, in B10 mice, NP-specific 
CD4 T cells would weaken the HA-specific B cell activation and the 
neutralizing Abs production.  
 
Help signals from activated CD4 T cells to B cells and CD8 T cells 
are mainly mediated by different cytokines. Cytokines from Th1 cells, like 
IL-2 and IFN-γ, can activate CD8 T cells and facilitate isotype switching to 
IgG2a/IgG2c; cytokines from Th2 cells, such as IL-4 and IL-5, mainly 
provide help for B cells activation and help IgA, IgE, and IgG1 production 
[34]. Therefore, we speculated that different cytokines profiles induced by 
i.n. NC infection might contribute to the IgG1/Th2 bias observed in DR1 Tg 
mice.  Results from Andrea’s lab showed that similar levels of IL-4, IL-2 
and IFN-γ were present in DR1 Tg mice after i.n. NC infection, while very 
minimal IL-4 was detected in B10 mice (data not shown). The Th2 type 
cytokine IL-4 in DR1 Tg mice quite possibly contributed to the IgG1/Th2 
bias, while the predominance of Th1 type cytokines in B10 mice enabled 
the B cell response to polarize towards a Th1 bias. In addition, Th1 type 
cytokines in B10 mice would effectively activate CD8 T cells, which might 
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explain the rapid virus clearance observed in B10 mice after i.n. NC 
infection. In the co-infection experiment, the production of IFN-γ and IL-6 
induced by MHV-68 infection might contribute to the isotype switching to 
IgG2c in DR1 Tg mice.   
 
In this study we also compared the virus-specific and non-specific B 
cell activation after NC infection between DR1 Tg mice and B10 mice. In 
B10 mice, the virus-specific B cell response in the MLN was accompanied 
by a strong non-specific ASCs production on days 8 and 10, displaying 
IgG2c predominance. Since the immune response was delayed during the 
early phase after NC infection in DR1 Tg mice, both the virus-specific and 
non-specific responses were weak on day 8. The increase of non-specific 
ASCs was not significant on days 10 and 14, except the non-specific IgG1 
ASCs. Research showed that strong and even normal virus-specific CD4 
T cell activation resulted in an increased early polyclonal B cell activation, 
which competed with the virus-specific B cell activation and the formation 
of neutralizing Abs [78]. Polyclonal B cell activation was reflected by non-
specific antibodies production and required the involvement of activated B 
cells in germinal center processes [79].  We speculated that the strong 
early non-specific B cell activation in B10 mice inhibited the virus-specific 
B cell activation and maybe responsible for the lower neutralizing Abs titer. 
But it was still unclear about the source and the function of the massive 
non-specific IgG1 ASCs in DR1 Tg mice. 
 
Since the germinal center (GC) is the main place supporting the 
somatic hypermutation, the affinity maturation, and the formation of 
memory B cells [68], we compared the GC reaction in MLNs after i.n. NC 
infection between DR1 Tg mice and B10 mice by staining lymphocytes 
with GC markers peanut agglutinin (PNA) and Fas (also known as CD95) 
[95, 96]. We calculated the total number of GC B cells per lymph node and 
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found no difference between two groups. We also calculated the GC B cell 
frequency per 106 lymphocytes, and there was no difference, except on 
day 21 after infection. However, there are alternative ways to examine the 
GC B cell response by using different GC markers combinations, such as 
B220+PNAhi, B220+Gl7hi, B220+IgDloFashiPNAhiCD38int, or 
B220+PNAhiGl7hiFashi [95-98]. When we compared the percent of 
B220+PNAhi population, there seemed to be a higher percentage of these 
cells in DR1 Tg mice than B10 mice. At this stage, the GC reaction has 
not been fully characterized in DR1 Tg mice and B10 mice, and it is still 
largely unclear whether the GC reaction is related to different immune 
response patterns. More experiments are needed in this direction in order 
to clarify this issue. 
 
In addition to GC B cells, there are two other important cell types that 
are also involved in the GC reaction, follicular DCs and follicular helper T 
cells [96, 99]. Both of them play crucial roles in the BCRs affinity selection 
in the GC. Follicular helper T cells are a subset of activated CD4 T cells 
and are characterized by high expression of CXCR5 and co-stimulatory 
molecules CD40L and ICOS [70]. Follicular helper T cells can secrete high 
level of IL-4 and shape the B cell response, especially the IgG1 isotype 
switching and affinity maturation [96]. It will be interesting to perform 
experiments that will compare follicular helper T cells frequencies between 
DR1 Tg mice and B10 mice. Understanding the mechanism underlying the 
unusual IgG1/Th2 bias in DR1 Tg mice after i.n. NC infection can provide 
useful insights into the regulation of immunoglobulin isotypes expression 
in DR1 Tg mice. 
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Figure 1. The primary influenza-specific ASCs response to intranasal 
administration of NC in DR1 Tg mice and B10 mice 
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Figure 2. The influenza-specific Abs level in serum after intranasal
administration of NC in DR1 Tg mice and B10 mice 
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and neutralizing Abs titers and hemagglutination
inhibition titers in serum after intranasal administration
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 Figure 4. Virus replication in the lung after intranasal 
infection of NC in DR1 Tg mice and B10 mice  
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Figure 5. Germinal center formation in the MLN of DR1 Tg mice and B10
mice after i.n. NC infection 
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Figure 8.  The influenza-specific ASCs response to intranasal 
administration of influenza virus PR8 in DR1 Tg mice and B10 mice 
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Figure 9. Influenza-specific Abs levels in serum after intranasal infection of
PR8 in DR1 Tg mice and B10 mice 
 
 
 
 
 
 
 66
A 
B 
virus titer in lung
6 8 10
0
2
4
6
8
DR1 Tg
B10
Days P.I.
TC
ID
50
 ( 
Lo
g1
0/
0.
2 
m
l )
 
8 10
16
64
256
1024
4096 DR1 Tg
B10
Days P.I.N
eu
tr
al
iz
in
g 
tit
er
 (r
ec
ip
ro
ca
l o
f d
ilu
tio
n)
 
 
 
 
 
Figure 10. Neutralizing Abs titers in serum and viral growth in the lung
after intranasal infection of PR8 in DR1 Tg mice and B10 mice 
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Figure 11. Influenza-specific ASCs responses in mice co-infected 
with NC and MHV-68 viruses 
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Figure 12. Influenza-specific Abs levels in serum of mice co-infected with 
NC and MHV-68 viruses 
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